Immuneering Corp-A 2026年季度报告

FORM 10-Q_________________________________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____________ toCommission File Number: 001-40675_________________________________________________ Immuneering Corporation Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorterperiod that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during thepreceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo TABLE OF CONTENTS PagePart IFinancial Information7Item 1.Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20257Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31,2026 and 20258Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 20259Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 202510Notes to Condensed Consolidated Financial Statements (Unaudited)11Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations26Item 3.Quantitative and Qualitative Disclosures about Market Risk37Item 4.Controls and Procedures37Part IIOther Information38Item 1.Legal Proceedings38Item 1A.Risk Factors38Item 2.Unregistered Sales of Equity Securities and Use of Proceeds100Item 3.Defaults Upon Senior Securities100Item 4.Mine Safety Disclosures100Item 5.Other Information100Item 6.Exhibits100Signatures102 FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements including within the meaning of the safe harbor provisions of thePrivate Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions forforward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terms suchas “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”“predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statementscontain these words. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including withoutlimitation statements regarding our plans to develop, manufacture and commercialize our product candidates (including whether as potentialmonotherapies or in combination with other therapeutic agents), the design, timing, disclosure of data, or outcome of our ongoing or plannedpreclinical studies or clinical trials involving atebimetinib (also referred to as IMM-1-104), any of our other pipeline product candidates andany future product candidates, the clinical utility of our product candidates when administered alone or in combination with other therapeuticagents, the filing with, and approval by, regulatory authorities of our product candidates, the sufficiency of funds to operate the business of theCompany and related expected cash runway, and our plans regarding raising additional capital, are forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectationsand projections about future events and financial trends that we believe may affect our busin